Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
Total Valuation
Indaptus Therapeutics has a market cap or net worth of $6.93M. The enterprise value is $3.63M.
Market Cap$6.93M
Enterprise Value$3.63M
Share Statistics
Indaptus Therapeutics has 14.43M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14.43M
Owned by Insiders11.26%
Owned by Instutions<0.01%
Financial Efficiency
Indaptus Therapeutics’s return on equity (ROE) is -3.81 and return on invested capital (ROIC) is -381.38%.
Return on Equity (ROE)-380.80%
Return on Assets (ROA)-204.69%
Return on Invested Capital (ROIC)-381.38%
Return on Capital Employed (ROCE)-389.51%
Revenue Per Employee$0
Profits Per Employee-$2,146,003.857
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Indaptus Therapeutics is -0.52. Indaptus Therapeutics’s PEG ratio is 0.04.
PE Ratio-0.52
PS Ratio0.00
PB Ratio2.00
Price to Fair Value2.00
Price to FCF-0.64
Price to Operating Cash Flow-0.64
PEG Ratio0.04
Income Statement
In the last 12 months, Indaptus Therapeutics had revenue of $0.00 and earned -$15.02M in profits. Earnings per share was -$1.61.
Revenue$0.00
Gross Profit$0.00
Operating Income-$15.37M
Pretax Income-$15.02M
Net Income-$15.02M
EBITDA-15.37M
Earnings Per Share (EPS)-1.61
Cash Flow
In the last 12 months, operating cash flow was -$12.32M and capital expenditures $0.00, giving a free cash flow of -$12.32M billion.
Operating Cash Flow-$12.32M
Free Cash Flow-$12.32M
Free Cash Flow per Share-$0.85
Dividends & Yields
Indaptus Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-156.42%
Earnings Yield-190.67%
Stock Price Statistics
Beta1.74
52-Week Price Change-82.08%
50-Day Moving Average0.71
200-Day Moving Average1.21
Relative Strength Index (RSI)34.24
Average Volume (3m)834.37K
Important Dates
Indaptus Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Indaptus Therapeutics as a current ratio of 1.95, with Debt / Equity ratio of 0.02
Current Ratio1.95
Quick Ratio1.95
Debt to Market Cap0.01
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Indaptus Therapeutics has paid $0.00 in taxes.
Income Tax$0.00
Effective Tax Rate0.00%
Enterprise Valuation
Indaptus Therapeutics EV to EBITDA ratio is -0.14, with an EV/FCF ratio of -0.18.
EV to Sales0.00
EV to EBITDA-0.14
EV to Free Cash Flow-0.18
EV to Operating Cash Flow-0.18
Balance Sheet
Indaptus Therapeutics has $5.79M in cash and marketable securities with $84.16K in debt, giving a net cash position of -$5.70M billion.
Cash & Marketable Securities$5.79M
Total Debt$84.16K
Net Cash-$5.70M
Net Cash Per Share-$0.40
Tangible Book Value Per Share$0.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Indaptus Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside900.00%
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast11.97%